DataSheet_2_NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia.docx حسب Lucero Valenzuela-Vázquez (14066019)

DataSheet_1_NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia.pdf حسب Lucero Valenzuela-Vázquez (14066019)

Behaviors with a significant main effect or interaction. حسب Grace Hecker (18813445)

No adverse effects after STX-S administration. حسب Mafalda Cacciottolo (16865905)

Quantifying time concordance based on first activation. حسب Anika Liu (8411805)

Inhibition of Timeless decreases A549 cell proliferation. حسب Ping Tian (697506)

Excessive LF4A kinase activity shortens cilia and decreases IFT. حسب Yu-Yang Jiang (7036916)

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. حسب Erika Kroll (20537020)

CFU-Mk is significantly decreased by GATA1s overexpression in <i>GATA1s</i> strains. حسب Shiori Matsuo (10492159)

Both MRI and SR-PCI demonstrated significant decreases in clinically-relevant articular cartilage parameters. حسب Suranjan Bairagi (17087667)

Geniposide (Gen) significantly decreased the content of Hyp in bleomycin-induced PF mice’s lung tissue. حسب Jian-Bin Yin (19556105)

Signal detection and analysis of sulfasalazine adverse reaction events based on the US FDA adverse event reporting database حسب Yikuan Du (16324215)

"…<p>Based on real data from the FDA Adverse Event Reporting System (FAERS), we explored and evaluated the adverse reactions (ADRs) of sulfasalazine (SSZ) in the first quarter of 2004–2023 to provide a reference basis and early warning for the safe use of SSZ in the clinic.…"

DataSheet_1_Decreasing Shortest Path Length of the Sensorimotor Network Induces Frontal Glioma-Related Epilepsy.pdf حسب Shengyu Fang (9134117)

"…Moreover, a decreased FC in the supplementary motor area and a shortening of the path’s length are additional characteristics of glioma-related epilepsy. …"

Top 10 most significant DEGs. حسب Foluwasomi A. Oyefeso (15999113)

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx حسب Qiong Jie (13270095)

"…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF حسب Qiong Jie (13270095)

"…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"

Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx حسب Qiong Jie (13270095)

"…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"

Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF حسب Qiong Jie (13270095)

"…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"

Counts of admissions comparing pre-pandemic (January 2019 –February 2020) to pandemic (March 2020 –March 2021) periods. حسب Jessica E. Long (6858170)

الموضوعات:

Service delivery and adverse birth outcomes comparing the pre-pandemic (January 2019 –February 2020) and pandemic (March 2020 –March 2021) periods, as well as the change in monthly... حسب Jessica E. Long (6858170)

الموضوعات: